These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 8180256)

  • 1. Viral safety issues: plasma-derived factor VIII.
    Berntorp E
    Ann Hematol; 1994; 68 Suppl 3():S35-6. PubMed ID: 8180256
    [No Abstract]   [Full Text] [Related]  

  • 2. [Plasma concentrates of factor VIII. Where are we?].
    Vicente V
    Sangre (Barc); 1989 Feb; 34(1):1-3. PubMed ID: 2496481
    [No Abstract]   [Full Text] [Related]  

  • 3. Concentrate safety and efficacy.
    Kasper CK
    Haemophilia; 2002 May; 8(3):161-5. PubMed ID: 12010404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment with plasma concentrates in hemophilia A. State Security and Health Planning Office. Expert Panel].
    Sangre (Barc); 1994 Apr; 39(2):157-61. PubMed ID: 8059299
    [No Abstract]   [Full Text] [Related]  

  • 5. UK: Hemophiliac wins access to recombinant factor VIII.
    Gold J
    Can HIV AIDS Policy Law Rev; 2003 Dec; 8(3):62. PubMed ID: 15108666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Virus in hemophilia: current status and future perspectives].
    Aguilar C; Félix Lucía J
    Sangre (Barc); 1996 Apr; 41(2):141-5. PubMed ID: 9045355
    [No Abstract]   [Full Text] [Related]  

  • 7. Who should use recombinant factor VIII?
    Hoots K
    Ann Hematol; 1994; 68 Suppl 3():S65-8. PubMed ID: 8180258
    [No Abstract]   [Full Text] [Related]  

  • 8. Fifteen years of population based experience in Finland with a plasma-derived monoclonal purified factor VIII concentrate.
    Mäkipernaa A; von Bonsdorff L
    Haemophilia; 2008 May; 14(3):612-4. PubMed ID: 18312362
    [No Abstract]   [Full Text] [Related]  

  • 9. Estimating the pathogen safety of manufactured human plasma products: application to fibrin sealants and to thrombin.
    Horowitz B; Busch M
    Transfusion; 2008 Aug; 48(8):1739-53. PubMed ID: 18466171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review of the transmission of hepatitis by clotting factor concentrates.
    Tabor E
    Scand J Haematol Suppl; 1984; 40():303-8. PubMed ID: 6433456
    [No Abstract]   [Full Text] [Related]  

  • 11. Long-term surveillance studies of previously untreated and treated patients, virally uninfected and infected patients--non-human viral transmission.
    Robertson JS
    Ann Hematol; 1994; 68 Suppl 3():S81-2. PubMed ID: 8180263
    [No Abstract]   [Full Text] [Related]  

  • 12. Purity of factor VIII concentrates.
    Goudemand J; Parquet-Gernez A; Goudemand M
    Blood Coagul Fibrinolysis; 1993 Jun; 4(3):499-500. PubMed ID: 8329577
    [No Abstract]   [Full Text] [Related]  

  • 13. Hemophiliacs sue Bayer over contaminated blood products.
    AIDS Policy Law; 2003 Jun; 18(12):7. PubMed ID: 12846189
    [No Abstract]   [Full Text] [Related]  

  • 14. Viral contamination of blood products.
    Thomas DP
    Lancet; 1994 Jun; 343(8913):1583-4. PubMed ID: 7911913
    [No Abstract]   [Full Text] [Related]  

  • 15. Long-term surveillance of HIV, HBV, and HCV infected patients.
    Shapiro A
    Ann Hematol; 1994; 68 Suppl 3():S87-8. PubMed ID: 8180264
    [No Abstract]   [Full Text] [Related]  

  • 16. Viral safety of plasma-derived factor VIII and IX concentrates.
    Ludlam CA
    Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S19-23. PubMed ID: 9351532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The potential impact of recombinant factor VIII on hemophilia care and the demand for blood and blood products.
    VanAken WG
    Transfus Med Rev; 1997 Jan; 11(1):6-14. PubMed ID: 9031486
    [No Abstract]   [Full Text] [Related]  

  • 18. [Blood-transmitted viral infections among haemophiliacs in Tunisia].
    Langar H; Triki H; Gouider E; Bahri O; Djebbi A; Sadraoui A; Hafsia A; Hafsia R
    Transfus Clin Biol; 2005 Oct; 12(4):301-5. PubMed ID: 16099190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Non-A non-B hepatitis caused by transfusing American antihemophilic globulin (factor VIII) in patients with hemophilia].
    Zhang Z; Li YH; Li XF
    Zhonghua Nei Ke Za Zhi; 1988 Feb; 27(2):82-4, 134. PubMed ID: 3141119
    [No Abstract]   [Full Text] [Related]  

  • 20. Safety of pasteurised factor VIII (haemate HS).
    Delvos V; Weidmann E; Hilfenhaus J; Mauler R
    Lancet; 1988 Nov; 2(8620):1141-2. PubMed ID: 2903355
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.